APOLLOHOSP
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Forvia agrees to sell Interiors business to Apollo funds for €1.82 billion
- Apollo-managed funds agreed to acquire Forvia Interiors at enterprise value EUR 1.82 billion.
- Closing is targeted by year-end.
- Interiors represented about 18% of Forvia revenue, generating about EUR 4.8 billion in 2025.
- Deal values business at 3.1x 2025 IFRS adjusted EBITDA of EUR 582 million.
- Forvia targets net debt reduction of at least EUR 1 billion, with proceeds earmarked for financial debt repayment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forvia SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270130OMX_____CNEWS_EN_GNW1001178046_en) on April 27, 2026, and is solely responsible for the information contained therein.
- Apollo-managed funds agreed to acquire Forvia Interiors at enterprise value EUR 1.82 billion.
- Closing is targeted by year-end.
- Interiors represented about 18% of Forvia revenue, generating about EUR 4.8 billion in 2025.
- Deal values business at 3.1x 2025 IFRS adjusted EBITDA of EUR 582 million.
- Forvia targets net debt reduction of at least EUR 1 billion, with proceeds earmarked for financial debt repayment.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forvia SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270130OMX_____CNEWS_EN_GNW1001178046_en) on April 27, 2026, and is solely responsible for the information contained therein.
MEDIA-Adani unit Refinances offshore bond with Apollo-backed funds - Bloomberg News
-- Source link: https://tinyurl.com/tkxycp3a
-- Note: Reuters has not verified this story and does not vouch for its accuracy
-- Source link: https://tinyurl.com/tkxycp3a
-- Note: Reuters has not verified this story and does not vouch for its accuracy
BREAKINGVIEWS-Temasek’s India hospital bet finds a pulse
The author is a Reuters Breakingviews columnist. The opinions expressed are her own.
By Ujjaini Dutta
BENGALURU, April 13 (Reuters Breakingviews) - Feverish demand for private medical care in India will aid Temasek as it lines up a $1.2 billion initial public offering of Manipal Hospitals, the country's largest chain with 12,000 beds. Yet at a mooted $13 billion valuation, the Singapore sovereign investor may be stretching too far to crystallise a strong exit on one of its rare controlling stakes.
Its 51% holding in Manipal is part of Temasek’s S$434 billion ($324 billion) global portfolio which boasts a growing footprint in India. The South Asian country accounts for about 8% of underlying assets, up from 5% a decade ago. Its exposure could rise higher in the coming years under Piyush Gupta; in November, Temasek appointed the former DBS Group DBSM.SI chief executive as its India chair. Manipal’s listing hands the bank its first IPO mandate in India.
The Singaporean investment firm valued the company at just under $5 billion in 2023 when it picked up a 41% stake for $2 billion. At the time, Manipal founder and Chair Ranjan Pai said the business needed "long-term patient capital". It has acquired five hospital brands since Temasek first invested in it in 2017. Meanwhile, revenue is set to grow 27% in the financial year to the end of March 2026, based on annualising results in the six months to the end of September in its IPO prospectus, with a 6% net profit margin.
At a time when global investors are cooling on Indian equities, it helps that Manipal's footprint is concentrated in the southern states where incomes are higher and patients older. Even so, the targeted headline valuation for the hospital chain would value it at 107 times its annualised first-half earnings, Breakingviews calculates, nearly double the multiple of its top three rivals Apollo Hospitals APLH.NS, Fortis Healthcare FOHE.NS and Max Healthcare MAXE.NS. Manipal is more efficient than its rivals yet its average revenue per bed is only about 5% higher than Apollo Hospitals' and 4% higher than Fortis Healthcare.
True, hospital valuations have swung wildly in India, with Apollo's nearly halving from two years ago but Temasek doesn't need such a grand debut for its bet on Manipal to stack up, and forcing one could cast a shadow over its ambitions to increase its exposure to the country.
Follow Ujjaini Dutta on LinkedIn and X
CONTEXT NEWS
India's Manipal Health Enterprises filed for an up to $1.17 billion initial public offering on March 23. The initial public offering comprises a fresh issue to raise $852.2 million and an offer for sale by existing investors including Singapore's Temasek, U.S. investment firm TPG, Manipal Education and Novo Holdings, according to its draft prospectus.
The company is targeting a valuation of up to $13 billion, Bloomberg reported on March 24, citing people familiar with the matter.
Manipal has expanded quickly via acquisitions since 2021 https://www.reuters.com/graphics/BRV-BRV/byprnxyrnpe/chart.png
(Editing by Una Galani; Production by Aditya Srivastav)
((For previous columns by the author, Reuters customers can click on DUTTA/[email protected]))
The author is a Reuters Breakingviews columnist. The opinions expressed are her own.
By Ujjaini Dutta
BENGALURU, April 13 (Reuters Breakingviews) - Feverish demand for private medical care in India will aid Temasek as it lines up a $1.2 billion initial public offering of Manipal Hospitals, the country's largest chain with 12,000 beds. Yet at a mooted $13 billion valuation, the Singapore sovereign investor may be stretching too far to crystallise a strong exit on one of its rare controlling stakes.
Its 51% holding in Manipal is part of Temasek’s S$434 billion ($324 billion) global portfolio which boasts a growing footprint in India. The South Asian country accounts for about 8% of underlying assets, up from 5% a decade ago. Its exposure could rise higher in the coming years under Piyush Gupta; in November, Temasek appointed the former DBS Group DBSM.SI chief executive as its India chair. Manipal’s listing hands the bank its first IPO mandate in India.
The Singaporean investment firm valued the company at just under $5 billion in 2023 when it picked up a 41% stake for $2 billion. At the time, Manipal founder and Chair Ranjan Pai said the business needed "long-term patient capital". It has acquired five hospital brands since Temasek first invested in it in 2017. Meanwhile, revenue is set to grow 27% in the financial year to the end of March 2026, based on annualising results in the six months to the end of September in its IPO prospectus, with a 6% net profit margin.
At a time when global investors are cooling on Indian equities, it helps that Manipal's footprint is concentrated in the southern states where incomes are higher and patients older. Even so, the targeted headline valuation for the hospital chain would value it at 107 times its annualised first-half earnings, Breakingviews calculates, nearly double the multiple of its top three rivals Apollo Hospitals APLH.NS, Fortis Healthcare FOHE.NS and Max Healthcare MAXE.NS. Manipal is more efficient than its rivals yet its average revenue per bed is only about 5% higher than Apollo Hospitals' and 4% higher than Fortis Healthcare.
True, hospital valuations have swung wildly in India, with Apollo's nearly halving from two years ago but Temasek doesn't need such a grand debut for its bet on Manipal to stack up, and forcing one could cast a shadow over its ambitions to increase its exposure to the country.
Follow Ujjaini Dutta on LinkedIn and X
CONTEXT NEWS
India's Manipal Health Enterprises filed for an up to $1.17 billion initial public offering on March 23. The initial public offering comprises a fresh issue to raise $852.2 million and an offer for sale by existing investors including Singapore's Temasek, U.S. investment firm TPG, Manipal Education and Novo Holdings, according to its draft prospectus.
The company is targeting a valuation of up to $13 billion, Bloomberg reported on March 24, citing people familiar with the matter.
Manipal has expanded quickly via acquisitions since 2021 https://www.reuters.com/graphics/BRV-BRV/byprnxyrnpe/chart.png
(Editing by Una Galani; Production by Aditya Srivastav)
((For previous columns by the author, Reuters customers can click on DUTTA/[email protected]))
Apollo Hospitals Says Further Bought Shares In Apollo Health And Lifestyle For 186.9 Million Rupees
April 10 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - FURTHER BOUGHT SHARES IN APOLLO HEALTH AND LIFESTYLE FOR 186.9 MILLION RUPEES
APOLLO HOSPITALS - SHAREHOLDING IN AHLL HAS NOW INCREASED TO 100%
Further company coverage: APLH.NS
(([email protected];))
April 10 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - FURTHER BOUGHT SHARES IN APOLLO HEALTH AND LIFESTYLE FOR 186.9 MILLION RUPEES
APOLLO HOSPITALS - SHAREHOLDING IN AHLL HAS NOW INCREASED TO 100%
Further company coverage: APLH.NS
(([email protected];))
Apollo Hospitals Approves Establishment Of Multi-Speciality Hospital At Dwarka, New Delhi
April 2 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - APPROVES ESTABLISHMENT OF MULTI-SPECIALITY HOSPITAL AT DWARKA, NEW DELHI
APOLLO HOSPITALS - LAND LICENSE PERIOD IS 55 YEARS
APOLLO HOSPITALS - ANNUAL LICENSE FEE OF 333 MILLION RUPEES FROM FIFTH YEAR
Source text: ID:nBSE2dpC6D
Further company coverage: APLH.NS
(([email protected];))
April 2 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - APPROVES ESTABLISHMENT OF MULTI-SPECIALITY HOSPITAL AT DWARKA, NEW DELHI
APOLLO HOSPITALS - LAND LICENSE PERIOD IS 55 YEARS
APOLLO HOSPITALS - ANNUAL LICENSE FEE OF 333 MILLION RUPEES FROM FIFTH YEAR
Source text: ID:nBSE2dpC6D
Further company coverage: APLH.NS
(([email protected];))
Apollo Hospitals Says Apollo Healthco Buys 100% Of Apollo Consumer Products For 900,000 Rupees
March 31 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS -APOLLO HEALTHCO BUYS 100% OF APOLLO CONSUMER PRODUCTS FOR 900,000 RUPEES
Source text: ID:nBSE4D8ydp
Further company coverage: APLH.NS
(([email protected];))
March 31 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS -APOLLO HEALTHCO BUYS 100% OF APOLLO CONSUMER PRODUCTS FOR 900,000 RUPEES
Source text: ID:nBSE4D8ydp
Further company coverage: APLH.NS
(([email protected];))
REFILE-Temasek-backed Manipal Health files for $1.2 billion India IPO
Corrects paragraph 4 in March 24 story to say Novo Holdings, not Novo Nordisk
India's Manipal Health files for IPO of up to $1.17 billion
Manipal Health is backed by Singapore's Temasek
Existing investors to sell up to $319.6 million worth of shares
By Vibhuti Sharma and Rishika Sadam
BENGALURU, March 24 (Reuters) - India's Manipal Health Enterprises filed for an up to $1.17 billion initial public offering on Tuesday, betting on rising demand for speciality care even as the domestic equities market faces volatility amid fragile global sentiment.
The initial public offering comprises a fresh issue to raise $852.2 million and an offer for sale of about 43.2 million shares by existing investors such as Singapore's Temasek, U.S. investment firm TPG TPG.O, Manipal Education and Novo Holdings, according to its draft prospectus.
Existing investors plan to sell up to 30 billion rupees ($319.58 million) worth of shares, according to two sources familiar with the matter. They did not want to be named because they were not authorised to speak to the media.
Demand for specialised healthcare has surged in the world's most populous country and is a key driver of growth, analysts say, a trend that is increasingly attracting private and foreign investment from firms such as Blackstone BX.N, Novo Holdings and KKR KKR.N.
India remains an undersupplied healthcare market, with strong tailwinds from rising insurance penetration, industry consolidation favouring larger players and higher per capita incomes driving demand for quality care, said Sanjay Singh, head of investment banking at InCred Capital, adding the IPO is likely to see strong interest from both institutional and retail investors.
Manipal's listed rival, Apollo Hospitals APLH.NS said revenue from complex care such as cardiology, oncology, and neurology rose 22.6% in the December 2025 quarter, highlighting growing demand for advanced medical care.
Manipal's IPO plans come amid a sharp slump in India's equities market, with global risk-off sentiment, tightening liquidity and sustained foreign outflows weighing.
Foreign investors have withdrawn more than $11.65 billion from Indian stocks so far in 2026, including more than $10.17 billion in March alone, according to depository data.
MANIPAL'S LAY OF THE LAND
As of September 30, Manipal had about 12,367 operational beds, while Apollo, valued at roughly $10.88 billion, has nearly 10,000 and targets 13,000 beds by fiscal 2030.
For the six months to September 2025, Manipal Health posted a consolidated net profit of 5.61 billion rupees and revenue of 47.13 billion rupees.
The company plans to use IPO proceeds to repay debt and to fund its acquisition of Sahyadri Hospitals, which it bought for $700 million.
($1 = 93.8725 Indian rupees)
(Reporting by Urvi Dugar in Bengaluru, writing by Chandini Monnappa; Editing by Janane Venkatraman and Thomas Derpinghaus)
(([email protected]; +91 9558725583;))
Corrects paragraph 4 in March 24 story to say Novo Holdings, not Novo Nordisk
India's Manipal Health files for IPO of up to $1.17 billion
Manipal Health is backed by Singapore's Temasek
Existing investors to sell up to $319.6 million worth of shares
By Vibhuti Sharma and Rishika Sadam
BENGALURU, March 24 (Reuters) - India's Manipal Health Enterprises filed for an up to $1.17 billion initial public offering on Tuesday, betting on rising demand for speciality care even as the domestic equities market faces volatility amid fragile global sentiment.
The initial public offering comprises a fresh issue to raise $852.2 million and an offer for sale of about 43.2 million shares by existing investors such as Singapore's Temasek, U.S. investment firm TPG TPG.O, Manipal Education and Novo Holdings, according to its draft prospectus.
Existing investors plan to sell up to 30 billion rupees ($319.58 million) worth of shares, according to two sources familiar with the matter. They did not want to be named because they were not authorised to speak to the media.
Demand for specialised healthcare has surged in the world's most populous country and is a key driver of growth, analysts say, a trend that is increasingly attracting private and foreign investment from firms such as Blackstone BX.N, Novo Holdings and KKR KKR.N.
India remains an undersupplied healthcare market, with strong tailwinds from rising insurance penetration, industry consolidation favouring larger players and higher per capita incomes driving demand for quality care, said Sanjay Singh, head of investment banking at InCred Capital, adding the IPO is likely to see strong interest from both institutional and retail investors.
Manipal's listed rival, Apollo Hospitals APLH.NS said revenue from complex care such as cardiology, oncology, and neurology rose 22.6% in the December 2025 quarter, highlighting growing demand for advanced medical care.
Manipal's IPO plans come amid a sharp slump in India's equities market, with global risk-off sentiment, tightening liquidity and sustained foreign outflows weighing.
Foreign investors have withdrawn more than $11.65 billion from Indian stocks so far in 2026, including more than $10.17 billion in March alone, according to depository data.
MANIPAL'S LAY OF THE LAND
As of September 30, Manipal had about 12,367 operational beds, while Apollo, valued at roughly $10.88 billion, has nearly 10,000 and targets 13,000 beds by fiscal 2030.
For the six months to September 2025, Manipal Health posted a consolidated net profit of 5.61 billion rupees and revenue of 47.13 billion rupees.
The company plans to use IPO proceeds to repay debt and to fund its acquisition of Sahyadri Hospitals, which it bought for $700 million.
($1 = 93.8725 Indian rupees)
(Reporting by Urvi Dugar in Bengaluru, writing by Chandini Monnappa; Editing by Janane Venkatraman and Thomas Derpinghaus)
(([email protected]; +91 9558725583;))
NSG agrees capital restructuring with Apollo including JPY 165 billion share investment
- NSG agreed with Apollo to implement capital restructuring measures.
- The plan includes a JPY 165.0 billion third-party share allotment to Apollo-managed funds.
- A share consolidation is planned to buy out existing shareholders, delist NSG, and make it privately held.
- Major financial institutions are expected to execute a JPY 140.0 billion debt-to-equity swap.
- Completion is expected in the second half of FY 2027, subject to shareholder and regulatory approvals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NSG - Nippon Sheet Glass Co. Ltd. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.
- NSG agreed with Apollo to implement capital restructuring measures.
- The plan includes a JPY 165.0 billion third-party share allotment to Apollo-managed funds.
- A share consolidation is planned to buy out existing shareholders, delist NSG, and make it privately held.
- Major financial institutions are expected to execute a JPY 140.0 billion debt-to-equity swap.
- Completion is expected in the second half of FY 2027, subject to shareholder and regulatory approvals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NSG - Nippon Sheet Glass Co. Ltd. published the original content used to generate this news brief on March 24, 2026, and is solely responsible for the information contained therein.
Apollo Hospitals Says Shareholding In AHLL Increases To 99.42%
March 23 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - SHAREHOLDING IN AHLL INCREASES TO 99.42%
Source text: ID:nNSE1Txnds
Further company coverage: APLH.NS
(([email protected];))
March 23 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - SHAREHOLDING IN AHLL INCREASES TO 99.42%
Source text: ID:nNSE1Txnds
Further company coverage: APLH.NS
(([email protected];))
Realty Income and Apollo form joint venture with USD 1 billion investment for 49% stake in U.S. retail portfolio
- Realty Income and Apollo agreed to form a joint venture in which Apollo-managed funds and affiliates will invest USD 1 billion for a 49% equity interest.
- The joint venture is expected to hold a portfolio of about 500 single-tenant U.S. retail properties under long-term net leases, with Realty Income managing the assets under a long-term management agreement.
- Realty Income will have a call option to redeem Apollo’s equity interest after year 7 through year 15, with a capped IRR of 6.88% for Apollo.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Realty Income Corporation published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.
- Realty Income and Apollo agreed to form a joint venture in which Apollo-managed funds and affiliates will invest USD 1 billion for a 49% equity interest.
- The joint venture is expected to hold a portfolio of about 500 single-tenant U.S. retail properties under long-term net leases, with Realty Income managing the assets under a long-term management agreement.
- Realty Income will have a call option to redeem Apollo’s equity interest after year 7 through year 15, with a capped IRR of 6.88% for Apollo.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Realty Income Corporation published the original content used to generate this news brief on March 19, 2026, and is solely responsible for the information contained therein.
Apollo buys USD 500 million of senior secured notes from Adani Energy Solutions subsidiary ATSOL Global IFSC
Apollo said Apollo-managed funds and affiliates purchased USD 500 million of investment-grade senior secured private placement notes from ATSOL Global IFSC, a subsidiary of Adani Energy Solutions. The financing is intended primarily to refinance bonds maturing in late 2026. Apollo said the notes are backed by ATSOL’s regulated power transmission assets in Western and Northern India.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apollo Global Management Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603111000PRIMZONEFULLFEED9670072) on March 11, 2026, and is solely responsible for the information contained therein.
Apollo said Apollo-managed funds and affiliates purchased USD 500 million of investment-grade senior secured private placement notes from ATSOL Global IFSC, a subsidiary of Adani Energy Solutions. The financing is intended primarily to refinance bonds maturing in late 2026. Apollo said the notes are backed by ATSOL’s regulated power transmission assets in Western and Northern India.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apollo Global Management Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603111000PRIMZONEFULLFEED9670072) on March 11, 2026, and is solely responsible for the information contained therein.
Brightstar Lottery plc publishes 2025 annual report
Brightstar Lottery published its annual report for the year ended December 31, 2025, highlighting its shift to operating as a pure-play lottery business following the sale of its IGT Gaming unit to an Apollo-managed holding company. The company said it continues to rely heavily on Italy, where about 18% of revenue came from Italian Lotto services and about 19% from Scratch & Win services. Brightstar noted it lost Allwyn UK as a customer after a system transition, which reduced revenue by USD 37 million in 2025. It also reported a USD 51 million reduction in an incentive payment, mainly due to lower MSJP activity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightstar Lottery plc published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.
Brightstar Lottery published its annual report for the year ended December 31, 2025, highlighting its shift to operating as a pure-play lottery business following the sale of its IGT Gaming unit to an Apollo-managed holding company. The company said it continues to rely heavily on Italy, where about 18% of revenue came from Italian Lotto services and about 19% from Scratch & Win services. Brightstar noted it lost Allwyn UK as a customer after a system transition, which reduced revenue by USD 37 million in 2025. It also reported a USD 51 million reduction in an incentive payment, mainly due to lower MSJP activity.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brightstar Lottery plc published the original content used to generate this news brief on March 09, 2026, and is solely responsible for the information contained therein.
Apollo Hospitals Posts Q3 Consol Net Profit 5.02 Billion Rupees
Feb 10 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS Q3 CONSOL NET PROFIT 5.02 BILLION RUPEES; IBES EST. 4.82 BILLION RUPEES
APOLLO HOSPITALS Q3 CONSOL REVENUE FROM OPERATIONS 64.77 BILLION RUPEES; IBES EST. 63.29 BILLION RUPEES
Further company coverage: APLH.NS
(([email protected];))
Feb 10 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS Q3 CONSOL NET PROFIT 5.02 BILLION RUPEES; IBES EST. 4.82 BILLION RUPEES
APOLLO HOSPITALS Q3 CONSOL REVENUE FROM OPERATIONS 64.77 BILLION RUPEES; IBES EST. 63.29 BILLION RUPEES
Further company coverage: APLH.NS
(([email protected];))
India Competition Commission Approves Acquisition Of Additional 30.58% Stake In Apollo Health And Lifestyle By Apollo Hospitals Enterprise
Jan 20 (Reuters) -
INDIA COMPETITION COMMISSION: APPROVES ACQUISITION OF ADDITIONAL 30.58% STAKE IN APOLLO HEALTH AND LIFESTYLE BY APOLLO HOSPITALS ENTERPRISE
Further company coverage: APLH.NS
(([email protected];))
Jan 20 (Reuters) -
INDIA COMPETITION COMMISSION: APPROVES ACQUISITION OF ADDITIONAL 30.58% STAKE IN APOLLO HEALTH AND LIFESTYLE BY APOLLO HOSPITALS ENTERPRISE
Further company coverage: APLH.NS
(([email protected];))
Apollo Hospitals Opens 400-Bed Facility In Pune
Nov 24 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - OPENS 400-BED FACILITY IN PUNE
Source text: ID:nPre7SYCra
Further company coverage: APLH.NS
(([email protected];;))
Nov 24 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - OPENS 400-BED FACILITY IN PUNE
Source text: ID:nPre7SYCra
Further company coverage: APLH.NS
(([email protected];;))
Apollo Hospitals To Set Up Comprehensive Oncology Facility At Gurugram At An Investment Of 5730 Million Rupees
Sept 12 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - TO SET UP COMPREHENSIVE ONCOLOGY FACILITY AT GURUGRAM AT AN INVESTMENT OF 5730 MILLION RUPEES
APOLLO HOSPITALS - TO ACQUIRE 31% STAKE HELD BY INTERNATIONAL FINANCE CORPORATION IN APOLLO HEALTH & LIFESTYLE
Source text: [ID:]
Further company coverage: APLH.NS
(([email protected];))
Sept 12 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - TO SET UP COMPREHENSIVE ONCOLOGY FACILITY AT GURUGRAM AT AN INVESTMENT OF 5730 MILLION RUPEES
APOLLO HOSPITALS - TO ACQUIRE 31% STAKE HELD BY INTERNATIONAL FINANCE CORPORATION IN APOLLO HEALTH & LIFESTYLE
Source text: [ID:]
Further company coverage: APLH.NS
(([email protected];))
Apollo Hospitals Says Promoter Group Sold 1.3% Stake Via Block Deal
Aug 22 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
PROMOTER GROUP, REPRESENTED BY SUNEETA REDDY, SOLD 1.3% STAKE VIA BLOCK DEAL
SALE PROCEEDS TO BE USED TO REDUCE PROMOTER GROUP DEBT
PROMOTER GROUP'S SHAREHOLDING REDUCED TO 28% FROM 29.3%
PROMOTER GROUP HAS NO PLANS FOR FURTHER STAKE REDUCTION
Source text: ID:nnAZN4EHRSU
Further company coverage: APLH.NS
(([email protected];;))
Aug 22 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
PROMOTER GROUP, REPRESENTED BY SUNEETA REDDY, SOLD 1.3% STAKE VIA BLOCK DEAL
SALE PROCEEDS TO BE USED TO REDUCE PROMOTER GROUP DEBT
PROMOTER GROUP'S SHAREHOLDING REDUCED TO 28% FROM 29.3%
PROMOTER GROUP HAS NO PLANS FOR FURTHER STAKE REDUCTION
Source text: ID:nnAZN4EHRSU
Further company coverage: APLH.NS
(([email protected];;))
Apollo Hospitals Announces Re-Organisation, Enabling Direct Listing Of Its Omni Channel Pharmacy And Digital Health Business
June 30 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
ANNOUNCES RE-ORGANISATION, ENABLING DIRECT LISTING OF ITS OMNI CHANNEL PHARMACY AND DIGITAL HEALTH BUSINESS
AHEL SHAREHOLDERS TO HAVE DIRECT SHAREHOLDING IN A COMBINED ENTITY
FOR EVERY 100 SHARES OF AHEL,AHEL SHAREHOLDERS WILL RECEIVE 195.2 SHARES OF NEW ENTITY
LISTING OF ENTITY EXPECTED IN 18-21 MONTHS
OMNI CHANNEL PHARMACY AND DIGITAL HEALTH BUSINESS PLANS TO ACHIEVE 250 BILLION RUPEES REVENUE BY FY27, 7% EBITDA MARGIN
AHEL WILL RETAIN 15% STAKE IN NEWCO
Source text: ID:nBSE20sh82
Further company coverage: APLH.NS
(([email protected];;))
June 30 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
ANNOUNCES RE-ORGANISATION, ENABLING DIRECT LISTING OF ITS OMNI CHANNEL PHARMACY AND DIGITAL HEALTH BUSINESS
AHEL SHAREHOLDERS TO HAVE DIRECT SHAREHOLDING IN A COMBINED ENTITY
FOR EVERY 100 SHARES OF AHEL,AHEL SHAREHOLDERS WILL RECEIVE 195.2 SHARES OF NEW ENTITY
LISTING OF ENTITY EXPECTED IN 18-21 MONTHS
OMNI CHANNEL PHARMACY AND DIGITAL HEALTH BUSINESS PLANS TO ACHIEVE 250 BILLION RUPEES REVENUE BY FY27, 7% EBITDA MARGIN
AHEL WILL RETAIN 15% STAKE IN NEWCO
Source text: ID:nBSE20sh82
Further company coverage: APLH.NS
(([email protected];;))
Adani's Mumbai Airport inks $750 million deal with Apollo-led investor group
June 23 (Reuters) - Mumbai International Airport Ltd, a subsidiary of Adani Airport Holdings, has secured a $750 million investment from a group led by affiliates of Apollo-managed funds APO.N and other long-term backers, the U.S. private capital group said on Monday.
The four-year unsecured notes will be used to refinance existing debt, with an option to raise an additional $250 million, Apollo said in a statement.
Adani Airports Holdings, the airport division of Adani Enterprises ADEL.NS, secured a $750 million investment earlier this month from a consortium of international banks.
The unit is expected to be spun off and listed by March 2027, according to a Bloomberg report from June.
Adani Airport Holdings currently operates eight airports across India and also oversees the Navi Mumbai International Airport, a strategically located project on the outskirts of Mumbai set become operational soon.
Adani Airport Holdings and Adani Enterprises did not immediately respond to requests for comment outside of business hours.
(Reporting by Chandni Shah in Bengaluru; Editing by Sherry Jacob-Phillips)
(([email protected];))
June 23 (Reuters) - Mumbai International Airport Ltd, a subsidiary of Adani Airport Holdings, has secured a $750 million investment from a group led by affiliates of Apollo-managed funds APO.N and other long-term backers, the U.S. private capital group said on Monday.
The four-year unsecured notes will be used to refinance existing debt, with an option to raise an additional $250 million, Apollo said in a statement.
Adani Airports Holdings, the airport division of Adani Enterprises ADEL.NS, secured a $750 million investment earlier this month from a consortium of international banks.
The unit is expected to be spun off and listed by March 2027, according to a Bloomberg report from June.
Adani Airport Holdings currently operates eight airports across India and also oversees the Navi Mumbai International Airport, a strategically located project on the outskirts of Mumbai set become operational soon.
Adani Airport Holdings and Adani Enterprises did not immediately respond to requests for comment outside of business hours.
(Reporting by Chandni Shah in Bengaluru; Editing by Sherry Jacob-Phillips)
(([email protected];))
Apollo Hospitals Plans To Commission Comprehensive Oncology Centre
March 4 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
PLANS TO COMMISSION COMPREHENSIVE ONCOLOGY CENTRE AT COST OF 2.5 BILLION RUPEES
Source text: ID:nNSE5W2Sw6
Further company coverage: APLH.NS
(([email protected];;))
March 4 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
PLANS TO COMMISSION COMPREHENSIVE ONCOLOGY CENTRE AT COST OF 2.5 BILLION RUPEES
Source text: ID:nNSE5W2Sw6
Further company coverage: APLH.NS
(([email protected];;))
Healthcare experts urge India to rewrite clinical trial rules to boost global market share
India's clinical trial share at 8%, compared to China's 29% as of 2022
Regulatory changes and tech investment needed for India
Advertising trials could improve patient recruitment in India
By Bhanvi Satija, Kashish Tandon and Rishika Sadam
HYDERABAD Feb 27 (Reuters) - India should take a page from the playbook of countries such as China and Australia if it wants a larger share of the global clinical trials market, healthcare experts said at an industry conference.
As of 2022, India held an 8% share in global clinical trials - which evaluate the safety and effectiveness of new treatments - compared to China's 29%, the U.S.'s 25%, and 38% for the rest of the world, data from consultancy PwC showed.
"There's a lot to learn from what other countries have done to make them clinical trial destinations," BCG India partner Smruthi Suryaprakash said, pointing out that China saw an increase in innovation after easing regulations, while Australia has benefited from offering significant tax incentives.
India's clinical trials research market is rapidly expanding, supported by a diverse patient base, cost-effective solutions, and a growing hospital network, according to U.S.-based GrandView Research, which forecasts revenues exceeding $2 billion by 2030.
"India will be able to capture the clinical trial (market) if we can really work on the speed. I think speed is what is really important to sponsors, either with regulator or being able to recruit patients faster," Suryaprakash added.
Suryaprakash, along with other experts, was speaking as part of a panel at the BioAsia conference in the southern Indian state of Telangana.
Rajeev Raghuvanshi, who heads India's drug regulator, said it was working to make the regulatory process more streamlined for global trials in India, based on feedback from stakeholders.
"We have aligned things every year on average for the last three years," the drugs controller general of India said.
The agency which revamped its trial rules in 2019, had approved about 160 trials in the last three years, he added.
RECRUITING THE RIGHT PATIENTS
Allowing sponsors to raise awareness among patients, such as through advertisements of ongoing studies, would also help India advance as a recruitment site, the experts said.
Advertising studies for experimental treatments could be helpful, especially for patients with rare diseases without many treatment options. It is a common practice in countries such as the U.S. and the U.K.
"You're not able to recruit into the trial because they (patients) do not know that it exists," said Padmaja Lokireddy, an oncologist at Apollo Hospitals APLH.NS.
That needs to change, experts said.
Some other experts highlighted challenges related to preparing a clinical trial site, ensuring it meets global safety standards and recruiting the right patients.
(Reporting by Bhanvi Satija, Kashish Tandon and Rishika Sadam in Hyderabad; Editing by Manas Mishra, Dhanya Skariachan and Tasim Zahid)
(([email protected]; Outside U.S. +91 9873062788;))
India's clinical trial share at 8%, compared to China's 29% as of 2022
Regulatory changes and tech investment needed for India
Advertising trials could improve patient recruitment in India
By Bhanvi Satija, Kashish Tandon and Rishika Sadam
HYDERABAD Feb 27 (Reuters) - India should take a page from the playbook of countries such as China and Australia if it wants a larger share of the global clinical trials market, healthcare experts said at an industry conference.
As of 2022, India held an 8% share in global clinical trials - which evaluate the safety and effectiveness of new treatments - compared to China's 29%, the U.S.'s 25%, and 38% for the rest of the world, data from consultancy PwC showed.
"There's a lot to learn from what other countries have done to make them clinical trial destinations," BCG India partner Smruthi Suryaprakash said, pointing out that China saw an increase in innovation after easing regulations, while Australia has benefited from offering significant tax incentives.
India's clinical trials research market is rapidly expanding, supported by a diverse patient base, cost-effective solutions, and a growing hospital network, according to U.S.-based GrandView Research, which forecasts revenues exceeding $2 billion by 2030.
"India will be able to capture the clinical trial (market) if we can really work on the speed. I think speed is what is really important to sponsors, either with regulator or being able to recruit patients faster," Suryaprakash added.
Suryaprakash, along with other experts, was speaking as part of a panel at the BioAsia conference in the southern Indian state of Telangana.
Rajeev Raghuvanshi, who heads India's drug regulator, said it was working to make the regulatory process more streamlined for global trials in India, based on feedback from stakeholders.
"We have aligned things every year on average for the last three years," the drugs controller general of India said.
The agency which revamped its trial rules in 2019, had approved about 160 trials in the last three years, he added.
RECRUITING THE RIGHT PATIENTS
Allowing sponsors to raise awareness among patients, such as through advertisements of ongoing studies, would also help India advance as a recruitment site, the experts said.
Advertising studies for experimental treatments could be helpful, especially for patients with rare diseases without many treatment options. It is a common practice in countries such as the U.S. and the U.K.
"You're not able to recruit into the trial because they (patients) do not know that it exists," said Padmaja Lokireddy, an oncologist at Apollo Hospitals APLH.NS.
That needs to change, experts said.
Some other experts highlighted challenges related to preparing a clinical trial site, ensuring it meets global safety standards and recruiting the right patients.
(Reporting by Bhanvi Satija, Kashish Tandon and Rishika Sadam in Hyderabad; Editing by Manas Mishra, Dhanya Skariachan and Tasim Zahid)
(([email protected]; Outside U.S. +91 9873062788;))
DIARY- India economic, corporate events on February 10
BENGALURU, Feb 10 (Reuters) - Diary of India economic, corporate events on Feb 10
ECONOMIC, CORPORATE .BSE500 EVENTS:
Start Date | Start Time | RIC | Company Name | Event Name |
10-Feb-2025 | NTS | APLH.NS | Apollo Hospitals Enterprise Ltd | Q3 2025 Apollo Hospitals Enterprise Ltd Earnings Release |
10-Feb-2025 | NTS | BATA.NS | Bata India Ltd | Q3 2025 Bata India Ltd Earnings Release |
10-Feb-2025 | NTS | EICH.NS | Eicher Motors Ltd | Q3 2025 Eicher Motors Ltd Earnings Release |
10-Feb-2025 | NTS | ELGE.NS | Elgi Equipments Ltd | Q3 2025 Elgi Equipments Ltd Earnings Release |
10-Feb-2025 | NTS | ENGI.NS | Engineers India Ltd | Q3 2025 Engineers India Ltd Earnings Release |
10-Feb-2025 | NTS | ESAB.NS | ESAB India Ltd | Q3 2025 ESAB India Ltd Earnings Release |
10-Feb-2025 | NTS | ESCO.NS | Escorts Kubota Ltd | Q3 2025 Escorts Kubota Ltd Earnings Release |
10-Feb-2025 | NTS | FSNE.NS | FSN E-Commerce Ventures Ltd | Q3 2025 Fsn E-Commerce Ventures Ltd Earnings Release |
10-Feb-2025 | NTS | GRWL.NS | Garware Technical Fibres Ltd | Q3 2025 Garware Technical Fibres Ltd Earnings Release |
10-Feb-2025 | NTS | GILE.NS | Gillette India Ltd | Q3 2025 Gillette India Ltd Earnings Release |
10-Feb-2025 | NTS | GRAS.NS | Grasim Industries Ltd | Q3 2025 Grasim Industries Ltd Earnings Release |
10-Feb-2025 | NTS | GSFC.NS | Gujarat State Fertilizers & Chemicals Ltd | Q3 2025 Gujarat State Fertilizers & Chemicals Ltd Earnings Release |
10-Feb-2025 | NTS | HBLO.NS | HBL Engineering Ltd | Q3 2025 HBL Power Systems Ltd Earnings Release |
10-Feb-2025 | NTS | NALU.NS | National Aluminium Co Ltd | Q3 2025 National Aluminium Co Ltd Earnings Release |
10-Feb-2025 | NTS | PAFO.NS | Patanjali Foods Ltd | Q3 2025 Patanjali Foods Ltd Earnings Release |
10-Feb-2025 | NTS | PNCI.NS | PNC Infratech Ltd | Q3 2025 PNC Infratech Ltd Earnings Release |
10-Feb-2025 | NTS | SPRC.NS | Sun Pharma Advanced Research Co Ltd | Q3 2025 Sun Pharma Advanced Research Co Ltd Earnings Release |
10-Feb-2025 | NTS | VARE.NS | Varroc Engineering Ltd | Q3 2025 Varroc Engineering Ltd Earnings Release |
10-Feb-2025 | NTS | CRSL.NS | CRISIL Ltd | Q4 2024 CRISIL Ltd Earnings Release |
10-Feb-2025 | NTS | VARB.NS | Varun Beverages Ltd | Q4 2024 Varun Beverages Ltd Earnings Release |
NTS - 'No time scheduled'
(Compiled by Bengaluru Newsroom)
BENGALURU, Feb 10 (Reuters) - Diary of India economic, corporate events on Feb 10
ECONOMIC, CORPORATE .BSE500 EVENTS:
Start Date | Start Time | RIC | Company Name | Event Name |
10-Feb-2025 | NTS | APLH.NS | Apollo Hospitals Enterprise Ltd | Q3 2025 Apollo Hospitals Enterprise Ltd Earnings Release |
10-Feb-2025 | NTS | BATA.NS | Bata India Ltd | Q3 2025 Bata India Ltd Earnings Release |
10-Feb-2025 | NTS | EICH.NS | Eicher Motors Ltd | Q3 2025 Eicher Motors Ltd Earnings Release |
10-Feb-2025 | NTS | ELGE.NS | Elgi Equipments Ltd | Q3 2025 Elgi Equipments Ltd Earnings Release |
10-Feb-2025 | NTS | ENGI.NS | Engineers India Ltd | Q3 2025 Engineers India Ltd Earnings Release |
10-Feb-2025 | NTS | ESAB.NS | ESAB India Ltd | Q3 2025 ESAB India Ltd Earnings Release |
10-Feb-2025 | NTS | ESCO.NS | Escorts Kubota Ltd | Q3 2025 Escorts Kubota Ltd Earnings Release |
10-Feb-2025 | NTS | FSNE.NS | FSN E-Commerce Ventures Ltd | Q3 2025 Fsn E-Commerce Ventures Ltd Earnings Release |
10-Feb-2025 | NTS | GRWL.NS | Garware Technical Fibres Ltd | Q3 2025 Garware Technical Fibres Ltd Earnings Release |
10-Feb-2025 | NTS | GILE.NS | Gillette India Ltd | Q3 2025 Gillette India Ltd Earnings Release |
10-Feb-2025 | NTS | GRAS.NS | Grasim Industries Ltd | Q3 2025 Grasim Industries Ltd Earnings Release |
10-Feb-2025 | NTS | GSFC.NS | Gujarat State Fertilizers & Chemicals Ltd | Q3 2025 Gujarat State Fertilizers & Chemicals Ltd Earnings Release |
10-Feb-2025 | NTS | HBLO.NS | HBL Engineering Ltd | Q3 2025 HBL Power Systems Ltd Earnings Release |
10-Feb-2025 | NTS | NALU.NS | National Aluminium Co Ltd | Q3 2025 National Aluminium Co Ltd Earnings Release |
10-Feb-2025 | NTS | PAFO.NS | Patanjali Foods Ltd | Q3 2025 Patanjali Foods Ltd Earnings Release |
10-Feb-2025 | NTS | PNCI.NS | PNC Infratech Ltd | Q3 2025 PNC Infratech Ltd Earnings Release |
10-Feb-2025 | NTS | SPRC.NS | Sun Pharma Advanced Research Co Ltd | Q3 2025 Sun Pharma Advanced Research Co Ltd Earnings Release |
10-Feb-2025 | NTS | VARE.NS | Varroc Engineering Ltd | Q3 2025 Varroc Engineering Ltd Earnings Release |
10-Feb-2025 | NTS | CRSL.NS | CRISIL Ltd | Q4 2024 CRISIL Ltd Earnings Release |
10-Feb-2025 | NTS | VARB.NS | Varun Beverages Ltd | Q4 2024 Varun Beverages Ltd Earnings Release |
NTS - 'No time scheduled'
(Compiled by Bengaluru Newsroom)
Apollo Hospitals Enterprise Says Healthco To Acquire Software Business From Searchlight Health
Dec 24 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS ENTERPRISE - HEALTHCO TO ACQUIRE SOFTWARE BUSINESS FROM SEARCHLIGHT HEALTH
APOLLO HOSPITALS ENTERPRISE - DEAL VALUED AT 675 MILLION RUPEES
Source text: ID:nNSE4g7SLs
Further company coverage: APLH.NS
(([email protected];))
Dec 24 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS ENTERPRISE - HEALTHCO TO ACQUIRE SOFTWARE BUSINESS FROM SEARCHLIGHT HEALTH
APOLLO HOSPITALS ENTERPRISE - DEAL VALUED AT 675 MILLION RUPEES
Source text: ID:nNSE4g7SLs
Further company coverage: APLH.NS
(([email protected];))
India's Aster DM to merge with Blackstone-backed Quality Care
Nov 29 (Reuters) - India's Aster DM Healthcare ATRD.NS will merge with Blackstone-backed hospitals operator Quality Care India, the companies said on Friday, bringing Aster closer to its larger rivals Apollo Hospitals and Manipal Hospitals.
This is Aster's first major deal since selling its Gulf business. The company will get access to Quality's 5,500 beds, taking the merged entity's total bed count to more than 10,000.
The acquisition will bring Aster's domestic capacity close to that of market leader Apollo Hospitals APLH.NS and the privately-held Manipal Hospitals, making it one of the top three hospital chains in the country.
The merged entity, which will be called Aster DM Quality Care, plans to add another 3,500 beds by fiscal year 2027, funded through internal accruals. Earlier this year, Aster laid out plans to spend up to $108 million to boost its domestic capacity across the 19 hospitals it runs in India.
The combined entity will be jointly controlled by Aster's top shareholders and Blackstone, with respective holdings of 24% and 30.7%. The company did not specify the size of the deal.
Post the merger, Aster's shareholders will hold a 57.3% stake in the combined firm, with Quality Care - which operates CARE Hospitals, KIMS Health and Evercare hospital chains in India - owning the rest.
Azad Moopen, Aster's founder and managing director, will continue in his role and oversee the merged entity, while Varun Khanna, MD of Quality Care, will helm the merged entity as the CEO, the two companies said.
(Reporting by Kashish Tandon in Bengaluru; Editing by Janane Venkatraman)
(([email protected]; 8800437922;))
Nov 29 (Reuters) - India's Aster DM Healthcare ATRD.NS will merge with Blackstone-backed hospitals operator Quality Care India, the companies said on Friday, bringing Aster closer to its larger rivals Apollo Hospitals and Manipal Hospitals.
This is Aster's first major deal since selling its Gulf business. The company will get access to Quality's 5,500 beds, taking the merged entity's total bed count to more than 10,000.
The acquisition will bring Aster's domestic capacity close to that of market leader Apollo Hospitals APLH.NS and the privately-held Manipal Hospitals, making it one of the top three hospital chains in the country.
The merged entity, which will be called Aster DM Quality Care, plans to add another 3,500 beds by fiscal year 2027, funded through internal accruals. Earlier this year, Aster laid out plans to spend up to $108 million to boost its domestic capacity across the 19 hospitals it runs in India.
The combined entity will be jointly controlled by Aster's top shareholders and Blackstone, with respective holdings of 24% and 30.7%. The company did not specify the size of the deal.
Post the merger, Aster's shareholders will hold a 57.3% stake in the combined firm, with Quality Care - which operates CARE Hospitals, KIMS Health and Evercare hospital chains in India - owning the rest.
Azad Moopen, Aster's founder and managing director, will continue in his role and oversee the merged entity, while Varun Khanna, MD of Quality Care, will helm the merged entity as the CEO, the two companies said.
(Reporting by Kashish Tandon in Bengaluru; Editing by Janane Venkatraman)
(([email protected]; 8800437922;))
MEDIA-Apollo-backed Global Schools Group is said to weigh stake sale - Bloomberg News
-- Source link: https://tinyurl.com/253e3z8p
-- Note: Reuters has not verified this story and does not vouch for its accuracy
((Bengaluru newsroom, [email protected]))
-- Source link: https://tinyurl.com/253e3z8p
-- Note: Reuters has not verified this story and does not vouch for its accuracy
((Bengaluru newsroom, [email protected]))
Apollo Hospitals Enterprise Q2 Consol Net Profit 3.79 Bln Rupees
Nov 6 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
Q2 CONSOL NET PROFIT 3.79 BILLION RUPEES; IBES EST. 3.64 BILLION RUPEES
Q2 CONSOL REV FROM OPS 55.89 BLN RUPEES; IBES EST. 55.13 BLN RUPEES
Source text: [ID:]
Further company coverage: APLH.NS
(([email protected];;))
Nov 6 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
Q2 CONSOL NET PROFIT 3.79 BILLION RUPEES; IBES EST. 3.64 BILLION RUPEES
Q2 CONSOL REV FROM OPS 55.89 BLN RUPEES; IBES EST. 55.13 BLN RUPEES
Source text: [ID:]
Further company coverage: APLH.NS
(([email protected];;))
Apollo Hospitals Plans To Add Over 3512 Capacity Beds Over Next 4 Yrs In 11 Locations In India
Nov 1 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - PLANS TO ADD OVER 3512 CAPACITY BEDS OVER NEXT 4 YRS IN 11 LOCATIONS IN INDIA
APOLLO HOSPITALS - TOTAL ESTIMATED PROJECT COST FOR THE 11 PROJECTS IS 61 BILLION RUPEES
Source text: ID:nNSE51p1hS
Further company coverage: APLH.NS
(([email protected];;))
Nov 1 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - PLANS TO ADD OVER 3512 CAPACITY BEDS OVER NEXT 4 YRS IN 11 LOCATIONS IN INDIA
APOLLO HOSPITALS - TOTAL ESTIMATED PROJECT COST FOR THE 11 PROJECTS IS 61 BILLION RUPEES
Source text: ID:nNSE51p1hS
Further company coverage: APLH.NS
(([email protected];;))
Apollo Hospitals Says India Competition Regulator CCI Approved Acquisition By Advent In Apollo Healthco
Aug 21 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - INDIA COMPETITION REGULATOR CCI APPROVED ACQUISITION BY ADVENT IN APOLLO HEALTHCO
APOLLO HOSPITALS - CCI ALSO APPROVED ACQUISITION BY CO IN KEIMED PVT LTD
APOLLO HOSPITALS - CCI ALSO APPROVED MERGER OF KEIMED INTO AHL
Source text for Eikon: ID:nNSE7fRB0M
Further company coverage: APLH.NS
(([email protected];))
Aug 21 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS - INDIA COMPETITION REGULATOR CCI APPROVED ACQUISITION BY ADVENT IN APOLLO HEALTHCO
APOLLO HOSPITALS - CCI ALSO APPROVED ACQUISITION BY CO IN KEIMED PVT LTD
APOLLO HOSPITALS - CCI ALSO APPROVED MERGER OF KEIMED INTO AHL
Source text for Eikon: ID:nNSE7fRB0M
Further company coverage: APLH.NS
(([email protected];))
Apollo Hospitals Enterprise Q1 Consol Net Profit 3.05 Billion Rupees
Aug 13 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS ENTERPRISE Q1 CONSOL NET PROFIT 3.05 BILLION RUPEES
APOLLO HOSPITALS ENTERPRISE Q1 CONSOL REVENUE FROM OPERATIONS 50.86 BILLION RUPEES
Further company coverage: APLH.NS
(([email protected];))
Aug 13 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS ENTERPRISE Q1 CONSOL NET PROFIT 3.05 BILLION RUPEES
APOLLO HOSPITALS ENTERPRISE Q1 CONSOL REVENUE FROM OPERATIONS 50.86 BILLION RUPEES
Further company coverage: APLH.NS
(([email protected];))
Apollo Hospitals Enterprise Q4 Consol Net Profit Misses Estimates
May 30 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS ENTERPRISE Q4 CONSOL NET PROFIT 2.54 BILLION RUPEES; LSEG IBES PROFIT EST. 2.65 BILLION RUPEES
APOLLO HOSPITALS ENTERPRISE Q4 CONSOL REVENUE FROM OPERATIONS 49.44 BILLION RUPEES; LSEG IBES EST. 49.43 BILLION RUPEES
APOLLO HOSPITALS ENTERPRISE LTD - DIVIDEND OF 10 RUPEES PER SHARE
APOLLO HOSPITALS ENTERPRISE YEAR AGO Q4 CONSOL PROFIT 1.45 BILLION RUPEES, REVENUE 43.02 BILLION RUPEES
APOLLO HOSPITALS ENTERPRISE LTD - REAPPOINTMENT OF PRATHAP C REDDY AS AN EXECUTIVE CHAIRMAN
Source text for Eikon: [ID:]
Further company coverage: APLH.NS
(([email protected];))
May 30 (Reuters) - Apollo Hospitals Enterprise Ltd APLH.NS:
APOLLO HOSPITALS ENTERPRISE Q4 CONSOL NET PROFIT 2.54 BILLION RUPEES; LSEG IBES PROFIT EST. 2.65 BILLION RUPEES
APOLLO HOSPITALS ENTERPRISE Q4 CONSOL REVENUE FROM OPERATIONS 49.44 BILLION RUPEES; LSEG IBES EST. 49.43 BILLION RUPEES
APOLLO HOSPITALS ENTERPRISE LTD - DIVIDEND OF 10 RUPEES PER SHARE
APOLLO HOSPITALS ENTERPRISE YEAR AGO Q4 CONSOL PROFIT 1.45 BILLION RUPEES, REVENUE 43.02 BILLION RUPEES
APOLLO HOSPITALS ENTERPRISE LTD - REAPPOINTMENT OF PRATHAP C REDDY AS AN EXECUTIVE CHAIRMAN
Source text for Eikon: [ID:]
Further company coverage: APLH.NS
(([email protected];))
Upcoming Events:
Quarterly Results
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Large Cap Ideas
See similar 'Large' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Apollo Hospital Ent. do?
Apollo Hospitals Enterprise is an integrated healthcare services provider. The company has emerged as Asia’s foremost integrated healthcare services provider and has a robust presence across the healthcare ecosystem, including Hospitals, Pharmacies, Primary Care & Diagnostic Clinics and several retail health models. With a strong presence across India, the company has redefined healthcare accessibility by bringing world-class medical expertise closer to the communities it serves. Its wide-reaching network of hospitals, clinics, pharmacies, and digital platforms ensures that quality care is always within reach. From metropolitan centres to remote regions, the company continues to bridge healthcare gaps, delivering care with quality, consistency and compassion.
Who are the competitors of Apollo Hospital Ent.?
Apollo Hospital Ent. major competitors are Max Healthcare Inst, Fortis Healthcare, Aster DM Healthcare, Narayana Hrudayalay, Global Health, Krishna Inst.Medi, RainbowChildrenS Med. Market Cap of Apollo Hospital Ent. is ₹1,11,261 Crs. While the median market cap of its peers are ₹36,623 Crs.
Is Apollo Hospital Ent. financially stable compared to its competitors?
Apollo Hospital Ent. seems to be less financially stable compared to its competitors. Altman Z score of Apollo Hospital Ent. is 7.24 and is ranked 7 out of its 8 competitors.
Does Apollo Hospital Ent. pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Apollo Hospital Ent. latest dividend payout ratio is 18.9% and 3yr average dividend payout ratio is 23.61%
How has Apollo Hospital Ent. allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Apollo Hospital Ent. balance sheet?
Balance sheet of Apollo Hospital Ent. is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Apollo Hospital Ent. improving?
Yes, profit is increasing. The profit of Apollo Hospital Ent. is ₹1,820 Crs for TTM, ₹1,446 Crs for Mar 2025 and ₹899 Crs for Mar 2024.
Is the debt of Apollo Hospital Ent. increasing or decreasing?
Yes, The net debt of Apollo Hospital Ent. is increasing. Latest net debt of Apollo Hospital Ent. is ₹4,075 Crs as of Sep-25. This is greater than Mar-25 when it was ₹2,570 Crs.
Is Apollo Hospital Ent. stock expensive?
Apollo Hospital Ent. is not expensive. Latest PE of Apollo Hospital Ent. is 61.75, while 3 year average PE is 81.21. Also latest EV/EBITDA of Apollo Hospital Ent. is 32.69 while 3yr average is 35.02.
Has the share price of Apollo Hospital Ent. grown faster than its competition?
Apollo Hospital Ent. has given lower returns compared to its competitors. Apollo Hospital Ent. has grown at ~20.14% over the last 3yrs while peers have grown at a median rate of 34.74%
Is the promoter bullish about Apollo Hospital Ent.?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Apollo Hospital Ent. is 28.02% and last quarter promoter holding is 28.02%.
Are mutual funds buying/selling Apollo Hospital Ent.?
The mutual fund holding of Apollo Hospital Ent. is decreasing. The current mutual fund holding in Apollo Hospital Ent. is 16.65% while previous quarter holding is 16.75%.